{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T22:32:33Z","timestamp":1791757953397,"version":"4.3.4"},"reference-count":138,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T00:00:00Z","timestamp":1595376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.01550","type":"journal-article","created":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T05:28:53Z","timestamp":1595395733000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":28,"title":["Specificity of the T Cell Response to Protein Biopharmaceuticals"],"prefix":"10.3389","volume":"11","author":[{"given":"Sylvain","family":"Meunier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"de Bourayne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moustafa","family":"Hamze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lien","family":"Azam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyne","family":"Correia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Menier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Maill\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,7,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1002\/art.21671","article-title":"Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis","volume":"54","author":"Wolbink","year":"2006","journal-title":"Arthritis Rheum"},{"key":"B2","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1136\/ard.2006.065615","article-title":"Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis","volume":"66","author":"Bartelds","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"B3","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/j.1398-9995.2009.02280.x","article-title":"Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions","volume":"65","author":"Vultaggio","year":"2010","journal-title":"Allergy"},{"key":"B4","doi-asserted-by":"publisher","first-page":"871","DOI":"10.7326\/0003-4819-132-11-200006060-00004","article-title":"Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial","volume":"132","author":"Seibold","year":"2000","journal-title":"Ann Intern Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1530\/eje.1.02021","article-title":"Impact of insulin antibodies on insulin aspart pharmacokinetics and pharmacodynamics after 12-week treatment with multiple daily injections of biphasic insulin aspart 30 in patients with type 1 diabetes","volume":"153","author":"Chen","year":"2005","journal-title":"Eur J Endocrinol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1056\/NEJM199603073341004","article-title":"Autoantibodies against erythropoietin in a patient with pure red-cell aplasia","volume":"334","author":"Casadevall","year":"1996","journal-title":"N Engl J Med"},{"key":"B7","first-page":"1353","article-title":"Immunogenicity of granulocyte-macrophage colony-stimulating factor (GM-CSF) products in patients undergoing combination therapy with GM-CSF","volume":"5","author":"Wadhwa","year":"1999","journal-title":"Clin Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1046\/j.1365-2249.2003.02113.x","article-title":"Anti-cytokine autoantibodies in autoimmunity: preponderance of neutralizing autoantibodies against interferon-alpha, interferon-omega and interleukin-12 in patients with thymoma and\/or myasthenia gravis","volume":"132","author":"Meager","year":"2003","journal-title":"Clin Exp Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/hae.13203","article-title":"SIPPET: methodology, analysis and generalizability","volume":"23","author":"Peyvandi","year":"2017","journal-title":"Haemophilia"},{"key":"B10","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1055\/s-0037-1621717","article-title":"Inhibitors in nonsevere hemophilia a: what is known and searching for the unknown","volume":"44","author":"Abdi","year":"2018","journal-title":"Semin Thromb Hemost"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1111\/jth.12958","article-title":"Hemophilia B: molecular pathogenesis and mutation analysis","volume":"13","author":"Goodeve","year":"2015","journal-title":"J Thromb Haemost"},{"key":"B12","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.coi.2017.08.014","article-title":"Negative selection, epitope mimicry and autoimmunity","volume":"49","author":"Rose","year":"2017","journal-title":"Curr Opin Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/nri3667","article-title":"Positive and negative selection of the T cell repertoire: what thymocytes see. (and don't see)","volume":"14","author":"Klein","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"96","DOI":"10.3389\/fimmu.2014.00096","article-title":"Differences in the composition of the human antibody repertoire by B cell subsets in the blood","volume":"5","author":"Mroczek","year":"2014","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1006\/geno.1993.1073","article-title":"Spectrum of mutations in CRM-positive and CRM-reduced hemophilia A","volume":"15","author":"McGinniss","year":"1993","journal-title":"Genomics"},{"key":"B16","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/BF00172063","article-title":"MHC ligands and peptide motifs: first listing","volume":"41","author":"Rammensee","year":"1995","journal-title":"Immunogenetics"},{"key":"B17","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/9858","article-title":"Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices [see comments]","volume":"17","author":"Sturniolo","year":"1999","journal-title":"Nat Biotechnol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nri3818","article-title":"The ins and outs of MHC class II-mediated antigen processing and presentation","volume":"15","author":"Roche","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1084\/jem.168.6.2091","article-title":"Mechanisms influencing the immunodominance of T cell determinants","volume":"168","author":"Adorini","year":"1988","journal-title":"J Exp Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/368215a0","article-title":"Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide","volume":"368","author":"Stern","year":"1994","journal-title":"Nature"},{"key":"B21","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1084\/jem.20011194","article-title":"Structure of a complex of the human alpha\/beta T cell receptor (TCR) HA1.7, influenza hemagglutinin peptide, and major histocompatibility complex class II molecule, HLA-DR4. (DRA*0101 and DRB1*0401): insight into TCR cross-restriction and alloreactivity","volume":"195","author":"Hennecke","year":"2002","journal-title":"J Exp Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S0065-2776(06)91002-5","article-title":"Accessibility control of V(D)J recombination","volume":"91","author":"Cobb","year":"2006","journal-title":"Adv Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1126\/science.286.5441.958","article-title":"A direct estimate of the human alphabeta T cell receptor diversity","volume":"286","author":"Arstila","year":"1999","journal-title":"Science"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1126\/science.288.5469.1135a","article-title":"Diversity of human alpha beta T cell receptors","volume":"288","author":"Arstila","year":"2000","journal-title":"Science"},{"key":"B25","doi-asserted-by":"publisher","first-page":"13139","DOI":"10.1073\/pnas.1409155111","article-title":"Diversity and clonal selection in the human T-cell repertoire","volume":"111","author":"Qi","year":"2014","journal-title":"Proc Natl Acad Sci USA."},{"key":"B26","doi-asserted-by":"publisher","first-page":"4135","DOI":"10.4049\/jimmunol.1102661","article-title":"The role of naive T cell precursor frequency and recruitment in dictating immune response magnitude","volume":"188","author":"Jenkins","year":"2012","journal-title":"J Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.immuni.2007.07.007","article-title":"Naive CD4(+) T cell frequency varies for different epitopes and predicts repertoire diversity and response magnitude","volume":"27","author":"Moon","year":"2007","journal-title":"Immunity"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.4049\/jimmunol.1102190","article-title":"Frequency of epitope-specific naive CD4(+) T cells correlates with immunodominance in the human memory repertoire","volume":"188","author":"Kwok","year":"2012","journal-title":"J Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.clim.2005.07.004","article-title":"Quantitative and qualitative assessment of circulating NY-ESO-1 specific CD4(+) T cells in cancer-free individuals","volume":"117","author":"Valmori","year":"2005","journal-title":"Clin Immunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.4049\/jimmunol.174.4.2404","article-title":"Monitoring of anti-vaccine CD4 T cell frequencies in melanoma patients vaccinated with a MAGE-3 protein","volume":"174","author":"Zhang","year":"2005","journal-title":"J Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"5757","DOI":"10.4049\/jimmunol.1300145","article-title":"Hierarchy of CD4 T cell epitopes of the ANRS Lipo5 synthetic vaccine relies on the frequencies of pre-existing peptide-specific T cells in healthy donors","volume":"190","author":"Castelli","year":"2013","journal-title":"J Immunol"},{"key":"B32","doi-asserted-by":"crossref","first-page":"29","DOI":"10.4049\/jimmunol.130.1.29","article-title":"In vitro immunization to KLH. II Limiting dilution analysis of antigen-reactive cells in primary and secondary culture","volume":"130","author":"Gebel","year":"1983","journal-title":"J Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1084\/jem.20090504","article-title":"Human naive and memory CD4+ T cell repertoires specific for naturally processed antigens analyzed using libraries of amplified T cells","volume":"206","author":"Geiger","year":"2009","journal-title":"J Exp Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1055\/s-0037-1614081","article-title":"Sensitization of CD4+ T cells to coagulation factor VIII: response in congenital and acquired hemophilia patients and in healthy subjects","volume":"84","author":"Reding","year":"2000","journal-title":"Thromb Haemost"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1046\/j.1538-7836.2003.00251.x","article-title":"Human CD4+ T-cell epitope repertoire on the C2 domain of coagulation factor VIII","volume":"1","author":"Reding","year":"2003","journal-title":"J Thromb Haemost"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1111\/j.1538-7836.2004.00850.x","article-title":"Epitope repertoire of human CD4(+) T cells on the A3 domain of coagulation factor VIII","volume":"2","author":"Reding","year":"2004","journal-title":"J Thromb Haemost"},{"key":"B37","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1182\/blood.V92.2.496","article-title":"Mechanism and kinetics of factor VIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor","volume":"92","author":"Jacquemin","year":"1998","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1182\/blood-2002-05-1369","article-title":"CD4+ T-cell clones specific for wild-type factor VIII: a molecular mechanism responsible for a higher incidence of inhibitor formation in mild\/moderate hemophilia A","volume":"101","author":"Jacquemin","year":"2003","journal-title":"Blood."},{"key":"B39","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1365-2516.2008.01905.x","article-title":"HLA-DR-restricted T-cell responses to factor VIII epitopes in a mild haemophilia A family with missense substitution A2201P","volume":"16","author":"Ettinger","year":"2010","journal-title":"Haemophilia"},{"key":"B40","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.cellimm.2015.09.007","article-title":"T cell response to FVIII","volume":"301","author":"Jacquemin","year":"2016","journal-title":"Cell Immunol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1182\/blood-2015-11-682468","article-title":"T cells from hemophilia A subjects recognize the same HLA-restricted FVIII epitope with a narrow TCR repertoire","volume":"128","author":"Ettinger","year":"2016","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1055\/s-0037-1614627","article-title":"Some factor VIII (FVIII) inhibitors recognise a FVIII epitope(s) that is present only on FVIII-vWF complexes","volume":"82","author":"Gilles","year":"1999","journal-title":"Thromb Haemost."},{"key":"B43","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1002\/ajh.2830420408","article-title":"Loss of high-responder inhibitors in patients with severe hemophilia A and human immunodeficiency virus type 1 infection: a report from the Multi-Center Hemophilia Cohort Study","volume":"42","author":"Bray","year":"1993","journal-title":"Am J Hematol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1055\/s-0037-1614450","article-title":"Inhibitor antibody development and T cell response to human factor VIII in murine hemophilia A","volume":"81","author":"Qian","year":"1999","journal-title":"Thromb Haemost"},{"key":"B45","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1160\/TH03-12-0755","article-title":"Immunodominant T-cell epitopes in the factor VIII C2 domain are located within an inhibitory antibody binding site","volume":"92","author":"Pratt","year":"2004","journal-title":"Thromb Haemost"},{"key":"B46","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1182\/blood-2011-08-374645","article-title":"CD4+ T-cell epitopes associated with antibody responses after intravenously and subcutaneously applied human FVIII in humanized hemophilic E17 HLA-DRB1*1501 mice","volume":"119","author":"Steinitz","year":"2012","journal-title":"Blood"},{"key":"B47","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jaut.2017.10.003","article-title":"Interferon-beta specific T cells are associated with the development of neutralizing antibodies in interferon-beta treated multiple sclerosis patients","volume":"88","author":"Kalluri","year":"2018","journal-title":"J Autoimmun"},{"key":"B48","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.clim.2005.08.017","article-title":"Clinical link between MHC class II haplotype and interferon-beta (IFN-beta) immunogenicity","volume":"118","author":"Barbosa","year":"2006","journal-title":"Clin Immunol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.ajhg.2008.07.006","article-title":"HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis","volume":"83","author":"Hoffmann","year":"2008","journal-title":"Am J Hum Genet"},{"key":"B50","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1002\/jps.24170","article-title":"Development of ADA against recombinant human interferon beta in immune tolerant mice requires rapid recruitment of CD4(+) T cells, induces formation of germinal centers but lacks susceptibility for (most) adjuvants","volume":"104","author":"Kijanka","year":"2015","journal-title":"J Pharm Sci"},{"key":"B51","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1182\/bloodadvances.2016001842","article-title":"T-cell assays confirm immunogenicity of tungsten-induced erythropoietin aggregates associated with pure red cell aplasia","volume":"1","author":"Rubic-Schneider","year":"2017","journal-title":"Blood Adv"},{"key":"B52","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1111\/cei.12858","article-title":"Circulating T cells to infliximab are mainly detectable in treated patients developing anti-drug antibodies and hypersensitivity reactions","volume":"186","author":"Vultaggio","year":"2016","journal-title":"Clin Exp Immunol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"500","DOI":"10.3389\/fimmu.2017.00500","article-title":"Characterization of CD4 T cell epitopes of infliximab and rituximab identified from healthy donors","volume":"8","author":"Hamze","year":"2017","journal-title":"Front Immunol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1136\/gutjnl-2015-309698","article-title":"Immunogenicity to infliximab is associated with HLA-DRB1","volume":"64","author":"Billiet","year":"2015","journal-title":"Gut"},{"key":"B55","doi-asserted-by":"publisher","first-page":"34482","DOI":"10.1074\/jbc.M114.615500","article-title":"Functional analysis of the anti-adalimumab response using patient-derived monoclonal antibodies","volume":"289","author":"van Schouwenburg","year":"2014","journal-title":"J Biol Chem"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1038\/s41591-019-0568-2","article-title":"A single T cell epitope drives the neutralizing anti-drug antibody response to natalizumab in multiple sclerosis patients","volume":"25","author":"Cassotta","year":"2019","journal-title":"Nat Med"},{"key":"B57","volume-title":"Guideline on Immunogenicity Assessment of Biotechnology-Derived Therapeutic Proteins","year":"2006"},{"key":"B58","first-page":"219","article-title":"Identification and removal of immunogenicity in therapeutic proteins","volume":"10","author":"Baker","year":"2007","journal-title":"Curr Opin Drug Discov Devel"},{"key":"B59","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1096\/fj.10-173872","article-title":"Quantitative analysis of the CD4 T-cell repertoire specific to therapeutic antibodies in healthy donors","volume":"25","author":"Delluc","year":"2011","journal-title":"Faseb J."},{"key":"B60","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.clim.2013.09.006","article-title":"T-cell dependent immunogenicity of protein therapeutics: preclinical assessment and mitigation","volume":"149","author":"Jawa","year":"2013","journal-title":"Clin Immunol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"e0178544","DOI":"10.1371\/journal.pone.0178544","article-title":"Quantitative analysis of the CD4+ T cell response to therapeutic antibodies in healthy donors using a novel T cell:PBMC assay","volume":"12","author":"Schultz","year":"2017","journal-title":"PLoS ONE."},{"key":"B62","doi-asserted-by":"publisher","first-page":"4542","DOI":"10.1182\/blood-2010-04-280875","article-title":"Quantification of the preexisting CD4 T-cell repertoire specific for human erythropoietin reveals its immunogenicity potential","volume":"116","author":"Delluc","year":"2010","journal-title":"Blood"},{"key":"B63","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1084\/jem.189.5.767","article-title":"Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes","volume":"189","author":"Chaux","year":"1999","journal-title":"J Exp Med"},{"key":"B64","first-page":"213","article-title":"NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells","volume":"62","author":"Zarour","year":"2002","journal-title":"Cancer Res"},{"key":"B65","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease","volume":"348","author":"Baert","year":"2003","journal-title":"N Engl J Med."},{"key":"B66","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1002\/art.21260","article-title":"Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study","volume":"52","author":"Pijpe","year":"2005","journal-title":"Arthritis Rheum"},{"key":"B67","doi-asserted-by":"publisher","first-page":"2970","DOI":"10.1002\/art.22046","article-title":"Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment","volume":"54","author":"Smith","year":"2006","journal-title":"Arthritis Rheum"},{"key":"B68","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s13555-018-0220-y","article-title":"Secukinumab demonstrates significantly lower immunogenicity potential compared to ixekizumab","volume":"8","author":"Spindeldreher","year":"2018","journal-title":"Dermatol Ther."},{"key":"B69","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1517\/14712598.7.3.405","article-title":"Immunogenicity screening in protein drug development","volume":"7","author":"Van Walle","year":"2007","journal-title":"Expert Opin Biol Ther"},{"key":"B70","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/bjd.13348","article-title":"Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis. (FEATURE)","volume":"172","author":"Blauvelt","year":"2015","journal-title":"Br J Dermatol"},{"key":"B71","first-page":"40","article-title":"The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis","volume":"25","author":"Dore","year":"2007","journal-title":"Clin Exp Rheumatol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/s41423-019-0304-3","article-title":"Impact of human sequences in variable domains of therapeutic antibodies on the location of CD4 T-cell epitopes","volume":"17","author":"Meunier","year":"2019","journal-title":"Cell Mol Immunol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1707418","DOI":"10.1080\/19420862.2019.1707418","article-title":"T cell epitope mapping of secukinumab and ixekizumab in healthy donors","volume":"12","author":"Spindeldreher","year":"2020","journal-title":"MAbs"},{"key":"B74","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.3389\/fimmu.2018.03113","article-title":"T cell response to infliximab in exposed patients: a longitudinal analysis","volume":"9","author":"Pratesi","year":"2018","journal-title":"Front Immunol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1080\/19420862.2018.1518888","article-title":"MHC-associated peptide proteomics enabling highly sensitive detection of immunogenic sequences for the development of therapeutic antibodies with low immunogenicity","volume":"10","author":"Sekiguchi","year":"2018","journal-title":"MAbs"},{"key":"B76","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.4049\/jimmunol.157.3.1037","article-title":"T cell recognition and tolerance of antibody diversity","volume":"157","author":"Eyerman","year":"1996","journal-title":"J Immunol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1084\/jem.20031234","article-title":"Activation and tolerance in CD4(+) T cells reactive to an immunoglobulin variable region","volume":"200","author":"Snyder","year":"2004","journal-title":"J Exp Med"},{"key":"B78","doi-asserted-by":"publisher","first-page":"82","DOI":"10.4049\/jimmunol.1002287","article-title":"Self-tolerance checkpoints in CD4 T cells specific for a peptide derived from the B cell antigen receptor","volume":"187","author":"Detanico","year":"2011","journal-title":"J Immunol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"17011","DOI":"10.1073\/pnas.1313001110","article-title":"Autoreactive thymic B cells are efficient antigen-presenting cells of cognate self-antigens for T cell negative selection","volume":"110","author":"Perera","year":"2013","journal-title":"Proc Natl Acad Sci USA."},{"key":"B80","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1016\/j.molimm.2006.09.029","article-title":"A molecular immunology approach to antibody humanization and functional optimization","volume":"44","author":"Lazar","year":"2007","journal-title":"Mol Immunol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"D413","DOI":"10.1093\/nar\/gku1056","article-title":"IMGT(R), the international ImMunoGeneTics information system(R) 25 years on","volume":"43","author":"Lefranc","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"B82","doi-asserted-by":"publisher","first-page":"3303","DOI":"10.1182\/blood-2008-02-138073","article-title":"Activation of natural regulatory T cells by IgG Fc-derived peptide \u201cTregitopes\u201d","volume":"112","author":"De Groot","year":"2008","journal-title":"Blood"},{"key":"B83","doi-asserted-by":"publisher","first-page":"16103","DOI":"10.1038\/s41598-019-52331-1","article-title":"Therapeutic administration of tregitope-human albumin fusion with insulin peptides to promote antigen-specific adaptive tolerance induction","volume":"9","author":"De Groot","year":"2019","journal-title":"Sci Rep"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.3389\/fimmu.2018.01701","article-title":"Antigen-specificity in the thymic development and peripheral activity of CD4(+)FOXP3(+) T regulatory cells","volume":"9","author":"Pohar","year":"2018","journal-title":"Front Immunol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"15480","DOI":"10.1038\/s41598-018-33680-9","article-title":"Tregitope-linked refined allergen vaccines for immunotherapy in cockroach allergy","volume":"8","author":"Prangtaworn","year":"2018","journal-title":"Sci Rep"},{"key":"B86","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1007\/s10875-012-9762-4","article-title":"In vitro and in vivo studies of IgG-derived Treg epitopes. (Tregitopes): a promising new tool for tolerance induction and treatment of autoimmunity","volume":"33","author":"Cousens","year":"2013","journal-title":"J Clin Immunol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1002\/iid3.167","article-title":"Tregitopes and impaired antigen presentation: Drivers of the immunomodulatory effects of IVIg?","volume":"5","author":"Sorde","year":"2017","journal-title":"Immun Inflamm Dis"},{"key":"B88","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jneuroim.2018.11.002","article-title":"Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study","volume":"326","author":"Jensen","year":"2019","journal-title":"J Neuroimmunol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1046\/j.1365-2249.1996.43747.x","article-title":"Antibodies to interferon (IFN) in hepatitis C patients relapsing while continuing recombinant IFN-alpha2 therapy","volume":"104","author":"Antonelli","year":"1996","journal-title":"Clin Exp Immunol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/BF02678213","article-title":"Treatment-induced antibodies to interleukin-2","volume":"10","author":"Prummer","year":"1997","journal-title":"Biotherapy"},{"key":"B91","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/0092-8674(91)90164-T","article-title":"Ablation of \u201ctolerance\u201d and induction of diabetes by virus infection in viral antigen transgenic mice","volume":"65","author":"Ohashi","year":"1991","journal-title":"Cell"},{"key":"B92","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.4049\/jimmunol.174.6.3187","article-title":"Rationally engineered therapeutic proteins with reduced immunogenicity","volume":"174","author":"Tangri","year":"2005","journal-title":"J Immunol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1111\/j.1537-2995.2008.01749.x","article-title":"Epoetin-associated pure red cell aplasia: past, present, and future considerations","volume":"48","author":"McKoy","year":"2008","journal-title":"Transfusion"},{"key":"B94","doi-asserted-by":"publisher","first-page":"3548","DOI":"10.1002\/jps.21672","article-title":"Evaluation of the immuno-stimulatory potential of stopper extractables and leachables by using dendritic cells as readout","volume":"98","author":"Mueller","year":"2009","journal-title":"J Pharm Sci"},{"key":"B95","doi-asserted-by":"publisher","first-page":"3507","DOI":"10.4049\/jimmunol.1800856","article-title":"Healthy donors exhibit a CD4 T cell repertoire specific to the immunogenic human hormone H2-relaxin before injection","volume":"202","author":"Azam","year":"2019","journal-title":"J Immunol"},{"key":"B96","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.jaci.2011.10.035","article-title":"Advanced glycation end products contribute to the immunogenicity of IFN-beta pharmaceuticals","volume":"129","author":"Bozhinov","year":"2012","journal-title":"J Allergy Clin Immunol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1038\/emboj.2009.212","article-title":"Thymus-specific deletion of insulin induces autoimmune diabetes","volume":"28","author":"Fan","year":"2009","journal-title":"Embo J."},{"key":"B98","doi-asserted-by":"publisher","first-page":"384","DOI":"10.2337\/diabetes.53.2.384","article-title":"Stratification of type 1 diabetes risk on the basis of islet autoantibody characteristics","volume":"53","author":"Achenbach","year":"2004","journal-title":"Diabetes"},{"key":"B99","doi-asserted-by":"publisher","first-page":"3636","DOI":"10.2337\/db13-0300","article-title":"Patterns of beta-cell autoantibody appearance and genetic associations during the first years of life","volume":"62","author":"Ilonen","year":"2013","journal-title":"Diabetes"},{"key":"B100","doi-asserted-by":"publisher","first-page":"172","DOI":"10.2337\/db14-0858","article-title":"Proinsulin-specific, HLA-DQ8, and HLA-DQ8-transdimer-restricted CD4+ T cells infiltrate islets in type 1 diabetes","volume":"64","author":"Pathiraja","year":"2015","journal-title":"Diabetes"},{"key":"B101","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1038\/nm.4203","article-title":"Analysis of self-antigen specificity of islet-infiltrating T cells from human donors with type 1 diabetes","volume":"22","author":"Babon","year":"2016","journal-title":"Nat Med"},{"key":"B102","doi-asserted-by":"publisher","first-page":"10732","DOI":"10.1073\/pnas.1809208115","article-title":"Proinsulin C-peptide is an autoantigen in people with type 1 diabetes","volume":"115","author":"So","year":"2018","journal-title":"Proc Natl Acad Sci USA."},{"key":"B103","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ymgme.2012.03.009","article-title":"Mapping the T helper cell response to acid alpha-glucosidase in Pompe mice","volume":"106","author":"Nayak","year":"2012","journal-title":"Mol Genet Metab"},{"key":"B104","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1111\/j.1538-7836.2005.01309.x","article-title":"Identification and removal of a promiscuous CD4+ T cell epitope from the C1 domain of factor VIII","volume":"3","author":"Jones","year":"2005","journal-title":"J Thromb Haemost"},{"key":"B105","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1111\/j.1538-7836.2007.02762.x","article-title":"T-cell responses over time in a mild hemophilia A inhibitor subject: epitope identification and transient immunogenicity of the corresponding self-peptide","volume":"5","author":"James","year":"2007","journal-title":"J Thromb Haemost"},{"key":"B106","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1111\/j.1538-7836.2011.04202.x","article-title":"T-cell responses in two unrelated hemophilia A inhibitor subjects include an epitope at the factor VIII R593C missense site","volume":"9","author":"James","year":"2011","journal-title":"J Thromb Haemost"},{"key":"B107","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1038\/nm.3270","article-title":"Endogenous factor VIII synthesis from the intron 22-inverted F8 locus may modulate the immunogenicity of replacement therapy for hemophilia A","volume":"19","author":"Pandey","year":"2013","journal-title":"Nat Med"},{"key":"B108","doi-asserted-by":"publisher","first-page":"M110002246","DOI":"10.1074\/mcp.M110.002246","article-title":"HLA-DR-presented peptide repertoires derived from human monocyte-derived dendritic cells pulsed with blood coagulation factor VIII","volume":"10","author":"van Haren","year":"2011","journal-title":"Mol Cell Proteomics."},{"key":"B109","doi-asserted-by":"publisher","first-page":"172","DOI":"10.3324\/haematol.2017.175083","article-title":"Comparative profiling of HLA-DR and HLA-DQ associated factor VIII peptides presented by monocyte-derived dendritic cells","volume":"103","author":"Peyron","year":"2018","journal-title":"Haematologica"},{"key":"B110","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1182\/bloodadvances.2018030452","article-title":"Peptides identified on monocyte-derived dendritic cells: a marker for clinical immunogenicity to FVIII products","volume":"3","author":"Jankowski","year":"2019","journal-title":"Blood Adv"},{"key":"B111","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1182\/blood-2006-05-022756","article-title":"VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors","volume":"109","author":"Dasgupta","year":"2007","journal-title":"Blood"},{"key":"B112","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1182\/bloodadvances.2017008706","article-title":"CD4 T cells specific for factor VIII are present at high frequency in healthy donors and comprise naive and memory cells","volume":"1","author":"Meunier","year":"2017","journal-title":"Blood Adv"},{"key":"B113","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1182\/blood-2016-06-720086","article-title":"Nonneutralizing antibodies against factor VIII and risk of inhibitor development in severe hemophilia A","volume":"129","author":"Cannavo","year":"2017","journal-title":"Blood"},{"key":"B114","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1084\/jem.185.5.833","article-title":"Tolerance to p53 by A2","volume":"185","author":"Theobald","year":"1997","journal-title":"J Exp Med."},{"key":"B115","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/j.immuni.2016.04.018","article-title":"Thymus-derived regulatory T cells are positively selected on natural self-antigen through cognate interactions of high functional avidity","volume":"44","author":"Kieback","year":"2016","journal-title":"Immunity"},{"key":"B116","doi-asserted-by":"publisher","first-page":"4034","DOI":"10.1182\/blood-2009-06-228155","article-title":"CD4+FOXP3+ regulatory T cells confer long-term regulation of factor VIII-specific immune responses in plasmid-mediated gene therapy-treated hemophilia mice","volume":"114","author":"Miao","year":"2009","journal-title":"Blood"},{"key":"B117","doi-asserted-by":"publisher","first-page":"e0006462","DOI":"10.1371\/journal.pntd.0006462","article-title":"Multi-parameter approach to evaluate the timing of memory status after 17DD-YF primary vaccination","volume":"12","author":"Costa-Pereira","year":"2018","journal-title":"PLoS Negl Trop Dis."},{"key":"B118","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1111\/j.1398-9995.2011.02589.x","article-title":"Immunological mechanisms of allergen-specific immunotherapy","volume":"66","author":"Jutel","year":"2011","journal-title":"Allergy"},{"key":"B119","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.jaci.2015.09.015","article-title":"Changes in markers associated with dendritic cells driving the differentiation of either TH2 cells or regulatory T cells correlate with clinical benefit during allergen immunotherapy","volume":"137","author":"Gueguen","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B120","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.4049\/jimmunol.1700008","article-title":"IL-10-producing infliximab-specific T cells regulate the antidrug T cell response in exposed patients","volume":"199","author":"Vultaggio","year":"2017","journal-title":"J Immunol"},{"key":"B121","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1172\/JCI2250","article-title":"Role of interleukin 10 in specific immunotherapy","volume":"102","author":"Akdis","year":"1998","journal-title":"J Clin Invest"},{"key":"B122","doi-asserted-by":"publisher","first-page":"4514","DOI":"10.4049\/jimmunol.180.7.4514","article-title":"Assessment of Bet v 1-specific CD4+ T cell responses in allergic and nonallergic individuals using MHC class II peptide tetramers","volume":"180","author":"Van Overtvelt","year":"2008","journal-title":"J Immunol"},{"key":"B123","doi-asserted-by":"publisher","first-page":"D405","DOI":"10.1093\/nar\/gku938","article-title":"The immune epitope database. (IEDB) 3.0","volume":"43","author":"Vita","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"B124","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1084\/jem.175.1.9","article-title":"The injection of deaggregated gamma globulins in adult mice induces antigen-specific unresponsiveness of T helper type 1 but not type 2 lymphocytes","volume":"175","author":"De Wit","year":"1992","journal-title":"J Exp Med"},{"key":"B125","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1038\/35021228","article-title":"Toll-like receptors in the induction of the innate immune response","volume":"406","author":"Aderem","year":"2000","journal-title":"Nature"},{"key":"B126","doi-asserted-by":"publisher","first-page":"e86322","DOI":"10.1371\/journal.pone.0086322","article-title":"Aggregation of human recombinant monoclonal antibodies influences the capacity of dendritic cells to stimulate adaptive T-cell responses in vitro","volume":"9","author":"Rombach-Riegraf","year":"2014","journal-title":"PLoS ONE."},{"key":"B127","first-page":"418","article-title":"Tissue and glomerular deposition of globulin aggregates","volume":"97","author":"Ginsburg","year":"1981","journal-title":"J Lab Clin Med."},{"key":"B128","doi-asserted-by":"publisher","first-page":"e15252","DOI":"10.1371\/journal.pone.0015252","article-title":"Trace levels of innate immune response modulating impurities (IIRMIs) synergize to break tolerance to therapeutic proteins","volume":"5","author":"Verthelyi","year":"2010","journal-title":"PLoS ONE."},{"key":"B129","doi-asserted-by":"publisher","first-page":"418","DOI":"10.4049\/jimmunol.1601246","article-title":"Crucial role for immune complexes but not FcRn in immunization against Anti-TNF-alpha antibodies after a single injection in mice","volume":"199","author":"Arnoult","year":"2017","journal-title":"J Immunol"},{"key":"B130","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.4049\/jimmunol.162.6.3663","article-title":"Elimination of the immunogenicity of therapeutic antibodies","volume":"162","author":"Gilliland","year":"1999","journal-title":"J Immunol"},{"key":"B131","doi-asserted-by":"publisher","first-page":"6658","DOI":"10.4049\/jimmunol.172.11.6658","article-title":"Elimination of an immunodominant CD4+ T cell epitope in human IFN-beta does not result in an in vivo response directed at the subdominant epitope","volume":"172","author":"Yeung","year":"2004","journal-title":"J Immunol"},{"key":"B132","doi-asserted-by":"publisher","first-page":"8571","DOI":"10.1073\/pnas.1405153111","article-title":"Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes","volume":"111","author":"Mazor","year":"2014","journal-title":"Proc Natl Acad Sci USA."},{"key":"B133","doi-asserted-by":"publisher","first-page":"e0138123","DOI":"10.1371\/journal.pone.0138123","article-title":"Characterisation of a novel anti-CD52 antibody with improved efficacy and reduced immunogenicity","volume":"10","author":"Holgate","year":"2015","journal-title":"PLoS ONE."},{"key":"B134","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1182\/bloodadvances.2017013482","article-title":"FVIII proteins with a modified immunodominant T-cell epitope exhibit reduced immunogenicity and normal FVIII activity","volume":"2","author":"Ettinger","year":"2018","journal-title":"Blood Adv"},{"key":"B135","doi-asserted-by":"publisher","first-page":"321","DOI":"10.2174\/156652311796150354","article-title":"Immune responses to AAV in clinical trials","volume":"11","author":"Mingozzi","year":"2011","journal-title":"Curr Gene Ther"},{"key":"B136","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/s41591-018-0204-6","article-title":"High prevalence of Streptococcus pyogenes Cas9-reactive T cells within the adult human population","volume":"25","author":"Wagner","year":"2019","journal-title":"Nat Med"},{"key":"B137","doi-asserted-by":"publisher","first-page":"3465","DOI":"10.4049\/jimmunol.1800774","article-title":"High-throughput single-cell sequencing of both TCR-beta alleles","volume":"201","author":"Hosoya","year":"2018","journal-title":"J Immunol"},{"key":"B138","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12896-017-0379-9","article-title":"Overview of methodologies for T-cell receptor repertoire analysis","volume":"17","author":"Rosati","year":"2017","journal-title":"BMC Biotechnol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.01550\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T16:54:24Z","timestamp":1696438464000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.01550\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,22]]},"references-count":138,"alternative-id":["10.3389\/fimmu.2020.01550"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.01550","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,22]]},"article-number":"1550"}}